| Variable . | Cases (n = 50) . | Controls (n = 157) . | P Value . |
|---|---|---|---|
| Age, y, median (range) | 43.0 (1 mo–77 y) | 49.0 (1 mo–85 y) | .14 |
| Sex, male | 30 (60) | 91 (58) | .93 |
| Immunocompromisea | 25 (50) | 67 (42.7) | .46 |
| Nonimmunocompromising medical conditionsb | 7 (14) | 69 (43.9) | .0003 |
| No recognized underlying condition | 18 (36) | 21 (13.4) | .0008 |
| Variable . | Cases (n = 50) . | Controls (n = 157) . | P Value . |
|---|---|---|---|
| Age, y, median (range) | 43.0 (1 mo–77 y) | 49.0 (1 mo–85 y) | .14 |
| Sex, male | 30 (60) | 91 (58) | .93 |
| Immunocompromisea | 25 (50) | 67 (42.7) | .46 |
| Nonimmunocompromising medical conditionsb | 7 (14) | 69 (43.9) | .0003 |
| No recognized underlying condition | 18 (36) | 21 (13.4) | .0008 |
Data are presented as No. (%) unless otherwise indicated.
aImmunodeficiency state or immunosuppressive therapy. Immunocompromising conditions included AIDS in 13, solid organ transplantation in 6, immunosuppressive therapy for inflammatory disorders in 5, and an uncharacterized immunodeficiency in 1 patient.
bNonimmunocompromising conditions included cerebral palsy, chronic pulmonary disease, hepatitis C, malignancy, pregnancy, and head trauma in 1 patient each.
| Variable . | Cases (n = 50) . | Controls (n = 157) . | P Value . |
|---|---|---|---|
| Age, y, median (range) | 43.0 (1 mo–77 y) | 49.0 (1 mo–85 y) | .14 |
| Sex, male | 30 (60) | 91 (58) | .93 |
| Immunocompromisea | 25 (50) | 67 (42.7) | .46 |
| Nonimmunocompromising medical conditionsb | 7 (14) | 69 (43.9) | .0003 |
| No recognized underlying condition | 18 (36) | 21 (13.4) | .0008 |
| Variable . | Cases (n = 50) . | Controls (n = 157) . | P Value . |
|---|---|---|---|
| Age, y, median (range) | 43.0 (1 mo–77 y) | 49.0 (1 mo–85 y) | .14 |
| Sex, male | 30 (60) | 91 (58) | .93 |
| Immunocompromisea | 25 (50) | 67 (42.7) | .46 |
| Nonimmunocompromising medical conditionsb | 7 (14) | 69 (43.9) | .0003 |
| No recognized underlying condition | 18 (36) | 21 (13.4) | .0008 |
Data are presented as No. (%) unless otherwise indicated.
aImmunodeficiency state or immunosuppressive therapy. Immunocompromising conditions included AIDS in 13, solid organ transplantation in 6, immunosuppressive therapy for inflammatory disorders in 5, and an uncharacterized immunodeficiency in 1 patient.
bNonimmunocompromising conditions included cerebral palsy, chronic pulmonary disease, hepatitis C, malignancy, pregnancy, and head trauma in 1 patient each.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
